Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms

18 Dec 2023

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Hematological disorders and diagnostics
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38154193
DOI: 10.1016/j.leukres.2023.107433

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasmsPMID 38154193Read ↗

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.Semantic proximity Read ↗

Comparison of the 2022 World Health Organization Classification and International Consensus Classification in Myelodysplastic Syndromes/NeoplasmsSemantic proximity Read ↗

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.Semantic proximity Read ↗

Impact of the International Consensus Classification of myelodysplastic syndromes.Semantic proximity Read ↗

Reclassification of Myelodysplastic Neoplasms According to the 2022 World Health Organization Classification and the 2022 International Consensus Classification Using Open-Source Data: Focus on SF3B1- and TP53-mutated Myelodysplastic Neoplasms.Semantic proximity Read ↗

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.Semantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Diagnosis and classification of myelodysplastic syndromesSemantic proximity Read ↗

Acute Myeloid Leukemia and Myelodysplastic Neoplasms: Clinical Implications of Myelodysplasia-Related Genes Mutations and TP53 AberrationsSemantic proximity Read ↗

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.Semantic proximity Read ↗

Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms.Semantic proximity Read ↗

Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.